Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

New Targeted Therapies and the Evolution of Urothelial Carcinoma Care

Learn how the experts leverage targeted therapies for optimal care of urothelial carcinoma in this on-demand Webcast from a live Webinar.
Petros Grivas, MD, PhD
Cora N. Sternberg, MD, FACP
Released: March 25, 2021

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Petros Grivas, MD, PhD

Associate Professor
Clinical Director
, Genitourinary Cancers Program
Division of Medical Oncology
Department of Medicine
University of Washington
Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance
Seattle, Washington

Petros Grivas, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis Oncology, Dyania, Driver, EMD Serono, Exelixis, Foundation Medicine, Genentech/Roche, Genzyme, GlaxoSmithKline, Immunomedics, Janssen, Merck, Mirati, Pfizer, and Seattle Genetics and funds for research support from Bavarian Nordic, Bristol-Myers Squibb, Clovis Oncology, Debiopharm, GlaxoSmithKline, Immunomedics, Kure It Cancer Research, Merck, Mirati Therapeutics, Pfizer, and QED Therapeutics.
Cora N. Sternberg, MD, FACP

Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Clinical Director, Englander Institute for Precision Medicine
Weill Cornell Medicine
New York-Presbyterian Hospital
New York, New York

Cora N. Sternberg, MD, FACP, has disclosed that she has received consulting fees from Astellas, AstraZeneca, Foundation Medicine, Immunomedics, Incyte, MSD, Pfizer, Roche/Genentech, and Sanofi/Genzyme.

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with urothelial carcinoma.

Goal

The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate new agents and recent findings into the treatment of patients with urothelial carcinoma.

Program Medium

This program has been made available online.

Related Content

Clinical Care Options (CCO): Expert analysis from Drs. Daniel Petrylak and Toni Choueiri on key data in genitourinary cancers from ASCO GU 2022

Toni K. Choueiri, MD Daniel P. Petrylak, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 18, 2022 Expired: April 17, 2023

Expert slides on key data from ASCO GU 2022 on prostate cancer, urothelial cancers, renal cell carcinoma, and more, from Clinical Care Options (CCO)

Released: February 28, 2022

Clinical Care Options (CCO): Joshua Sabari, MD, provides insights into the emerging targeted therapies for patients with NRG1-positive solid tumors

Joshua Sabari, MD Released: February 28, 2022

Expert commentary previewing key studies at 2022 ASCO Genitourinary Cancers Symposium annual meeting, from Clinical Care Options (CCO)

Toni K. Choueiri, MD Daniel P. Petrylak, MD Released: February 15, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Immunomedics, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings